Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 1
1991 1
1992 1
1993 2
1994 3
1995 6
1996 4
1997 7
1998 9
1999 14
2000 5
2001 9
2002 6
2003 7
2004 5
2005 6
2006 6
2007 9
2008 6
2009 8
2010 12
2011 15
2012 14
2013 15
2014 17
2015 21
2016 29
2017 30
2018 31
2019 17
2020 15
2021 25
2022 15
2023 16
2024 15
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: kornblau sm. J Clin Oncol. 2025 Jun 13:JCO2500640. doi: 10.1200/JCO-25-00640. Online ahead of print. J Clin Oncol. 2025. PMID: 40513054
Targetable BIRC5 dependency in therapy-resistant TP53 mutated acute myeloid leukemia.
Mamdouh AM, Lim FQ, Mi Y, Olesinski EA, Chan CGT, Jasdanwala S, Lin XX, Wang Y, Tan JYM, Bhatia KS, Sapozhnikova V, Wang C, Mahesh AN, Liang DTE, Chitkara N, Mertins P, Hogdal L, Brown BD, Haferlach T, Lobry C, Lindsley C, Puissant A, Ho HK, Das S, Letai A, Kornblau SM, Krönke J, Ayoub E, Itahana K, Andreeff M, Bhatt S. Mamdouh AM, et al. Among authors: kornblau sm. bioRxiv [Preprint]. 2025 May 22:2025.05.17.654633. doi: 10.1101/2025.05.17.654633. bioRxiv. 2025. PMID: 40475516 Free PMC article. Preprint.
Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin.
Escherich CS, Li Z, Barnett KR, Li Y, Walker M, Yoshimura S, Yang W, Huang X, Yu J, Stock W, Paietta E, Konopleva MY, Kornblau SM, Jabbour E, Litzow MR, Inaba H, Pui CH, Loh ML, Evans WE, Savic D, Yang JJ. Escherich CS, et al. Among authors: kornblau sm. Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215. Online ahead of print. Blood. 2025. PMID: 40435412
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza A, Root J, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau S, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Reville PK, et al. Among authors: kornblau s. Blood. 2025 Jun 19;145(25):3015-3029. doi: 10.1182/blood.2024027244. Blood. 2025. PMID: 40179376 Free PMC article.
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.
Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. Swaminathan M, et al. Among authors: kornblau sm. Blood Cancer J. 2025 Apr 2;15(1):52. doi: 10.1038/s41408-025-01265-1. Blood Cancer J. 2025. PMID: 40175328 Free PMC article. No abstract available.
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.
Mosialou I, Ali AM, Labella R, Bisikirska B, Cuesta-Dominguez A, Vgenopoulou P, Reyes I, Rao SM, Wang A, Luo N, Galan-Diez M, Zhao J, Chernak BJ, Bewersdorf JP, Fukasawa K, Su J, Higa J, Adams RA, Corper AL, Pampou S, Woods CM, Fan X, Shah RP, Feldstein J, Liu N, Liang C, Heiblig M, Kornblau S, Garcia-Manero G, Berman E, Jurcic JG, Rabadan R, Raza A, Kousteni S. Mosialou I, et al. Among authors: kornblau s. Cancer Cell. 2025 Jun 9;43(6):1007-1024.e13. doi: 10.1016/j.ccell.2025.03.007. Epub 2025 Mar 27. Cancer Cell. 2025. PMID: 40154481
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: kornblau s. Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25. Leukemia. 2025. PMID: 40000842 Free PMC article. Clinical Trial.
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. Bouligny IM, et al. Among authors: kornblau s. Haematologica. 2025 Jul 1;110(7):1628-1633. doi: 10.3324/haematol.2024.286559. Epub 2025 Feb 20. Haematologica. 2025. PMID: 39973365 Free PMC article. No abstract available.
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.
Escherich CS, Moriyama T, Li Z, Hsiao YC, Yang W, Li Y, Reyes N, Walker M, Budhraja A, Bhatara S, Diaz-Flores E, Stock W, Paietta E, Konopleva MY, Kornblau SM, Litzow MR, Inaba H, Pui CH, Opferman JT, Loh ML, Yu J, O'Brien MM, Evans WE, Yang JJ. Escherich CS, et al. Among authors: kornblau sm. Blood. 2025 Mar 13;145(11):1182-1194. doi: 10.1182/blood.2024026085. Blood. 2025. PMID: 39791601
371 results